Severe Colitis Caused by Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma

Internal Medicine - Japan
doi 10.2169/internalmedicine.3340-19
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Internal Medicine

Related search

Myeloid-Derived Suppressor Cells Correlate With Patient Outcomes in Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2016English

A Prognostic Evaluation of Hepatic Arterial Injection Chemotherapy With Cisplatin Suspended in Lipiodol for Hepatocellular Carcinoma.

Drug Delivery System
Pharmaceutical Science
1990English

Hepatic Arterial Infusion Chemotherapy.

Drug Delivery System
Pharmaceutical Science
1997English

Effect of Body Composition on Survival Benefit of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Comparison With Sorafenib Therapy

PLoS ONE
Multidisciplinary
2019English

Significance of Trans-Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Oncology Reports
MedicineCancer ResearchOncology
1994English

Hepatic Arterial Infusion of Chemotherapy for Hepatic Metastases From Colorectal Cancer

Cancer Control
MedicineOncologyHematology
2006English

The Study of Pirarubicin-Emulsion for Hepatic Arterial Infusion Chemotherapy.

Drug Delivery System
Pharmaceutical Science
1997English

Study of Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer Patients With Synchronous Liver Metastases

The journal of the Japanese Practical Surgeon Society
1993English

Randomized, Phase II Trial of Sequential Hepatic Arterial Infusion Chemotherapy and Sorafenib Versus Sorafenib Alone as Initial Therapy for Advanced Hepatocellular Carcinoma: SCOOP-2 Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy